Nomura has maintained a Buy rating on Cipla with a target price of ₹1,810, implying an upside of approximately 18% from the current market price of ₹1,535.00.
The brokerage stated that Q1FY26 results were in line with its estimates. It remains optimistic about a recovery in Cipla’s domestic business and a healthy pipeline of product launches in the US market.
Despite the expected decline in generic Revlimid (gRevlimid) sales, Cipla’s management guided for revenue growth in FY26 and projected EBITDA margins between 23.5% and 24.5%, supporting the positive outlook.
Disclaimer: This article is based on Nomura’s brokerage report and does not constitute investment advice. Please consult a certified financial advisor before making any investment decisions.
